The QualityStocks Daily Thursday, September 14th, 2023

Today's Top 3 Investment Newsletters

Green Car Stocks(NKLA) $1.1500 +32.24%

InsiderTrades(MODV) $33.7600 +15.42%

Stocks to Buy Now(MULN) $0.5700 +14.94%

The QualityStocks Daily Stock List

HopTo Inc. (HPTO)

QualityStocks, StockEarnings, StocksEarning, MarketBeat, SmallCapVoice, Money Morning, Marketbeat.com, Wall Street Mover, TopPennyStockMovers, Tiny Gems, PoliticsAndMyPortfolio, PennyStocks24 and Money Map Press reported earlier on HopTo Inc. (HPTO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

hopTo Inc. (OTC: HPTO) is a company focused on the development and sale of application publishing software globally.

The firm has its headquarters in Concord, New Hampshire and was incorporated in May 1996 by Walter Keller. Prior to its name change in September 2013, the firm was known as GraphOn Corp. It operates as part of the software-application industry, under the technology sector. The firm mainly serves consumers in the United States, Japan, Brazil, the Netherlands and Germany.

The enterprise’s application publishing software includes application virtualization and cloud computing software for a range of computer operating systems, including UNIX, Windows and various Linux-based variants. It offers its application publishing software solutions under the GO-Global brand name. The enterprise provides GO-Global, an application access solution that offers cross-platform remote access and Web-enabled access to existing software applications, as well as the deployment of secure and private cloud environments for use and/or resale by independent software vendors, corporate enterprises, governmental and educational institutions, and others. Its GO-Global software products comprise GO-Global for UNIX, which allows access to UNIX and Linux-based applications from remote locations and internet connections; GO-Global for Windows that allows access to Windows-based applications from remote locations and internet connections; and GO-Global Client that allows remote application access from various local, remote, and mobile platforms, including UNIX, Windows, Linux, Apple OS X and iOS, and Google Android. The enterprise sells its products through resellers, including system integrators, original equipment manufacturers, distributors and value-added resellers. It serves small to medium-sized companies, independent software vendors, departments within large corporations and governmental and educational institutions.

The company remains committed to bolstering its overall growth and creating value for its shareholders.

HopTo Inc. (HPTO), closed Thursday's trading session at $0.39, up 34.4828%, on 27,744 volume. The average volume for the last 3 months is 8,084 and the stock's 52-week low/high is $0.29/$0.599.

Rubellite Energy (RUBLF)

MarketBeat reported earlier on Rubellite Energy (RUBLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rubellite Energy Inc. (OTC: RUBLF) (TSE: RBY) is an energy firm focused on exploring for, developing, producing and selling heavy crude oil from the Clearwater Formation in Eastern Alberta, using multi-lateral drilling technology.

The firm has its headquarters in Calgary, Canada and was incorporated in 2021, on July 12th. It operates as part of the oil and gas E&P industry, under the energy sector. The firm primarily serves consumers in Canada.

The company operates as a subsidiary of Perpetual Energy Inc. It has a pureplay Clearwater asset base and is pursuing a robust organic growth plan focused on superior corporate returns and funds flow generation while maintaining a conservative capital structure and prioritizing environmental, social and governance ("ESG") excellence.

The enterprise’s Clearwater Assets comprise of about 298 net sections of acreage, for conventional heavy crude oil in the formation with approximately over 370 identified multi-lateral drilling locations. The assets also include two dimensional (2D) and three dimensional (3D) seismic data and a road network of roughly 40km. The enterprise has 11 producing multi-lateral wells, including 2 producing wells at Figure Lake, 5 wells at Marten Hills and the 10 original producing wells at Ukalta.

The firm, which recently announced its latest financial results, remains committed to pursuing a robust organic growth plan focused on superior corporate returns and prioritization of ESG excellence. This may in turn influence shareholder value positively.

Rubellite Energy (RUBLF), closed Thursday's trading session at $1.75, even for the day, on 500 volume. The average volume for the last 3 months is 29,970 and the stock's 52-week low/high is $1.21/$2.20.

Argentina Lithium & Energy (PNXLF)

We reported earlier on Argentina Lithium & Energy (PNXLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Argentina Lithium & Energy Corp. (OTCQB: PNXLF) (CVE: LIT) (FRA: OAY3) is a junior mineral exploration firm that is focused on acquiring, exploring for and evaluating natural resource properties in Argentina and the Americas.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2000, on April 11th. Prior to its name change in September 2016, the firm was known as Iron South Mining Corp. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The company’s projects include the Antofalla North Lithium Project, the Incahuasi Lithium Project, the Pocitos Project and the Rincon West Project. The Antofalla North controls roughly 10,050 hectares of mining concessions in the Salar de Antofalla, distributed between the adjacent provinces of Salta and Catamarca. The Incahuasi Project includes a 100% interest in over 25,000 hectares of the Incahuasi Salar and basin in Catamarca Province. The company has an option to earn a 100% interest in approximately 15,857 hectares of claims in 11 contiguous mining concessions located on the west side of the Pocitos Salar. It also holds a 100% interest in 460.5 hectares and has an option to earn a 100% interest in a further 3,282 hectares of claims located at the Rincon Salar in Salta Province, Argentina.

The firm, which recently gave a corporate update on its operations, is focused on advancing exploration efforts at its projects and bringing in additional value for its shareholders.

Argentina Lithium & Energy (PNXLF), closed Thursday's trading session at $0.1511, off by 4.0635%, on 200 volume. The average volume for the last 3 months is 284,980 and the stock's 52-week low/high is $0.13895/$0.2934.

American Cannabis Company (AMMJ)

QualityStocks, Promotion Stock Secrets, InvestorPlace, Marketbeat.com, CFN Media Group, Money Morning, Wealth Insider Alert, Stock News Now, The Street, Cannabis Financial Network News, Market Intelligence Center Alert, TheOTCInvestor, Energy & Resources Digest, Daily Trade Alert, Wall Street Daily and MarketBeat reported earlier on American Cannabis Company (AMMJ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American Cannabis Company Inc. (OTCQB: AMMJ) is a company engaged in the provision of solutions for businesses operating in the regulated cannabis industry in Canada and the United States.

The firm has its headquarters in Lakewood, Colorado and was incorporated in 2001. It operates as part of the consulting services industry, under the industrials sector. The firm serves consumers in the U.S. and Canada.

The enterprise provides clean, green solutions to existing and aspiring participants in the cannabis and hemp industries as well as consulting services for firms associated with the cannabis industry in different stages of development, such as cannabis license applications, business planning, growth strategies and monitoring, as well as cultivation build-out oversight, cannabis regulatory compliance, and compliance audit services. It also sells products and equipment used in the cultivation, processing, transportation or retail sale of cannabis, such as High Density Cultivation System, which ensures that space is used in an efficient manner; The Satchel, a pouch-like case designed as a child-proof exit package solution for the regulated cannabis industry; The Cultivation Cube, a self-contained and scalable cultivation system; SoHum Living Soil, a just-add-water soil; and other products for cultivation operations, medicinal and recreational cannabis dispensary operations, and infused-products. In addition to this, the enterprise offers advisory and consulting services to design industry-specific products and facilities; and manages a strategic group partnership that offers customer products commonly used in the industry.

The company remains committed to better meeting consumer needs via its products and generating value for its shareholders.

American Cannabis Company (AMMJ), closed Thursday's trading session at $0.0485, off by 10.1852%, on 1,468,039 volume. The average volume for the last 3 months is 17,817 and the stock's 52-week low/high is $0.0101/$0.087.

C21 Investments (CXXIF)

TradersPro reported earlier on C21 Investments (CXXIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

C21 Investments Inc. (OTCQX: CXXIF) (CNSX: CXXI) is a vertically integrated cannabis firm that is focused on cultivating, processing, distributing and selling cannabis and hemp-derived consumer products.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1987, on January 15th. Prior to its name change in November 2017, the firm was known as Curlew Lake Resources Inc. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers in the United States, Mexico and Canada.

The enterprise operates through a single segment; the Nevada segment. This segment is involved in the cultivation and manufacturing of cannabis flower products, vape products and extract products for wholesale and retail sales. It owns Silver State Relief and Silver State Cultivation in Nevada, including legacy Oregon brands Phantom Farms, Hood Oil and Eco Firma Farms. These brands produce and distribute a range of cannabidiol (CBD) and tetrahydrocannabinol (THC) products from cannabis flower, pre-rolls, cannabis oil, vaporizer cartridges and edibles. The enterprise conducts its business through its 14 subsidiaries in the U. S., including 320204 Oregon Holdings Corp., 320204 Re Holdings LLC; 320204 US Holdings Corp. and 320204 Nevada Holdings Corp, among others.

The company, whose latest financial results show increases in its revenues, remains committed to generating positive cash flow and actively assessing all strategic opportunities through the lens of value creation for its shareholders.

C21 Investments (CXXIF), closed Thursday's trading session at $0.3582, off by 1.863%, on 9,507 volume. The average volume for the last 3 months is 198,801 and the stock's 52-week low/high is $0.176/$0.3689.

Grom Social Enterprises Inc. (GROM)

Broad Street, QualityStocks, MarketClub Analysis, AwesomeStocks, InvestorPlace, The Stock Dork, Money Wealth Matters, BUYINS.NET, StocksEarning and StockEarnings reported earlier on Grom Social Enterprises Inc. (GROM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Grom (NASDAQ: GROM) recently closed its previously announced underwritten public offering of 946,000 units, each at a price to the public of $3.00, and 54,000 pre-funded units, each at a price to the public of $2.999, for aggregate gross proceeds of approximately $3.0 million. In addition, the company granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock and/or pre-funded warrants to purchase up to 150,000 shares of common stock and/or Series A warrants to purchase up to 150,000 shares of common stock and/or Series B warrants to purchase up to 150,000 shares of common stock, solely to cover over-allotments, if any, less underwriting discounts and commissions. On Sept. 8, 2023, the underwriters exercised the option to purchase an additional 150,000 Series A warrants and 150,000 Series B warrants. Grom intends to use the net proceeds from the offering for working capital and general corporate purposes. EF Hutton, division of Benchmark Investments, LLC, acted as sole book running manager for the offering. Lucosky Brookman LLP acted as legal counsel to the company, and Carmel, Milazzo & Feil LLP acted as legal counsel to EF Hutton.

To view the full press release, visit http://ibn.fm/Vm3qd

About Grom Social Enterprises Inc.

Grom is an emerging social media platform and original content provider of entertainment for children under 13, which provides safe and secure digital environments for kids that can be monitored by their parents or guardians. The company has several operating subsidiaries, including Grom Social, which delivers its content through mobile and desktop environments (web portal and apps) that entertain children and lets them interact with friends, access relevant news, and play proprietary games while teaching them about being good digital citizens, and Curiosity Ink Media, a global media company that develops, acquires, builds, grows, and maximizes the short-, mid- and long-term commercial potential of Kids & Family entertainment properties and associated business opportunities. The company also owns and operates Top Draw Animation, which produces award-winning animation content for some of the largest international media companies in the world. The company also includes Grom Educational Services, which provides web filtering for K-12 schools, government and private businesses. For more information, please visit https://gromsocial.com or for investor relations, please visit http://investors.gromsocial.com.

Grom Social Enterprises Inc. (GROM), closed Thursday's trading session at $2.24, off by 1.7544%, on 477,037 volume. The average volume for the last 3 months is 2.262M and the stock's 52-week low/high is $1.95/$270.00.

American Rebel Holdings Inc. (AREB)

QualityStocks, MoneyTV, StockWireNews, StockStreetWire, MarketClub Analysis, Fierce Analyst, The Stock Dork, Small Cap Firm and InvestorPlace reported earlier on American Rebel Holdings Inc. (AREB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American Rebel (NASDAQ: AREB, AREBW) is a designer, manufacturer and marketer of branded safes and personal security and self-defense products as well as branded apparel and accessories. The company recently completed a $3.3 million warrant inducement. EF Hutton, division of Benchmark Investments, LLC, acted as agent for the offering.

For more information, visit https://ibn.fm/elxec

About American Rebel Holdings Inc.

American Rebel operates primarily as a designer, manufacturer and marketer of branded safes and personal security and self-defense products. The company also designs and produces branded apparel and accessories. To enhance the strength of its brand and drive product demand, the company works with manufacturing facilities and various suppliers to emphasize product quality and mechanical development in order to improve the performance and affordability of its products while providing support to its distribution channel and consumers. The company seeks to sell products that offer features and benefits of higher-end safes at mid-line price ranges. Through its growing network of dealers, the company promotes and sells its products in select regional retailers and local specialty safe, sporting goods, hunting and firearms stores, as well as online, including its website and e-commerce platforms such as Amazon.com.

American Rebel Holdings Inc. (AREB), closed Thursday's trading session at $0.7603, off by 3.796%, on 518,109 volume. The average volume for the last 3 months is 382,827 and the stock's 52-week low/high is $0.742/$18.685.

Green Thumb Industries Inc. (GTBIF)

InvestorPlace, MarketBeat, Wealth Insider Alert, Daily Trade Alert, Trades Of The Day, TradersPro, The Street, QualityStocks, The Online Investor, CFN Media Group, Cabot Wealth, StreetInsider, Trading For Keeps, wyatt research newsletter, Zacks, Kiplinger Today, Top Pros' Top Picks, Daily Profit and Technology Profits Daily reported earlier on Green Thumb Industries Inc. (GTBIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The chairman of a key Senate committee has revealed that he discussed the possibility of advancing bipartisan cannabis banking legislation within the next six weeks with Senate Majority Leader Chuck Schumer. During a recent interview with Punchbowl News, Senate Banking Committee chair Sherrod Brown said that he talked to Schumer about moving the Secure and Fair Enforcement (SAFE) Banking Act alongside several other major bills within the next one and a half months.

Cannabis banking has been a contentious issue since states began legalizing medical and recreational cannabis in the United States nearly two decades ago. Although dozens of states now have legal cannabis programs, federal law still classifies marijuana as a Schedule I drug with no medical application. As a result of federal prohibition, licensed cannabis operators find it nigh impossible to access critical financial services such as banking, cashless payments, capital and financial aid.

This forces cannabis businesses to operate on a mostly cash-only basis and puts these businesses at significant risk of violent robberies, something that has been occurring in recent months with increasing frequency. The SAFE Banking Act was introduced to address the lack of access to financial services in America’s multibillion-dollar cannabis industry.

In a recent floor speech and in a letter to fellow lawmakers, Schumer said providing the cannabis industry with access to banking is a priority. He noted that although “making progress on cannabis” via banking legislation was a legislative priority, the legislation wouldn’t progress on the Senate floor without bipartisan support on cannabis reform and related issues, including capping insulin prices and competing with China on the global scale. Additionally, spending legislation will take up a lot of the Senators’ time in the next few weeks, likely reducing the time they have to discuss cannabis banking.

One key section of the SAFE Banking Act (Section 10) has also been subject to intense debate among lawmakers in recent months and even prevented the measure from passing during the summer legislative session.

In late July, Schumer said lawmakers having bipartisan negotiations over the SAFE Banking Act were “making good progress.” The Senate Majority leader reportedly told a lobbyist at the time that Senate lawmakers were working on cannabis banking. He had previously stated that he wished to address marijuana banking reform during the summer session but constant debate over sections of the cannabis banking bill have kept the measure from advancing until the end of the session.

The marijuana industry and its leading entities such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) have heard such promises before and are unlikely to get too excited by these new pronouncements until actual banking reform is enacted at the federal level.

Green Thumb Industries Inc. (GTBIF), closed Thursday's trading session at $11.54, up 5.8716%, on 351,637 volume. The average volume for the last 3 months is 558,941 and the stock's 52-week low/high is $6.42/$16.50.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, Kiplinger Today, MarketBeat, Daily Trade Alert, Top Pros' Top Picks, Cabot Wealth, Profit Trends, MarketClub Analysis, Wealth Insider Alert, StreetInsider, Early Bird, QualityStocks, The Online Investor, The Street, Trades Of The Day, Trading For Keeps, wyatt research newsletter, StreetAuthority Daily, TradersPro, Investment U, Wyatt Investment Research, Daily Profit, CFN Media Group and Schaeffer's reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Maryland’s marijuana market achieved another milestone last month, with retailers notching almost $92 million in sales, marking the state’s second month of recreational cannabis sales. This surge represents a significant leap from July’s $87 million, illustrating the transformative impact of expanding cannabis access beyond the medical sector, more than doubling prior sales figures.

Data recently released by the state’s cannabis regulator, MCA, indicates that legal dispensaries tallied sales exceeding $91.7 million. Smokeable flower sales were in the lead at $55.1 million, followed by concentrates at $24.7 million, while infused edibles and nonedibles contributed $6.2 million and $5.2 million, respectively. Trim or shake products brought in $512,991, with marijuana plants contributing $9,588.

July saw a surge in marijuana sales, coinciding with the enactment of a law allowing the state’s medical stores to serve all adults aged 21 years and older. The opening weekend of this transition resulted in an impressive $10 million in cannabis product sales.

Multistate operators (MSOs) have emerged as prominent players in Maryland’s cannabis market, with companies such as Ascend, GTI, Verona and Curaleaf reporting the highest sales figures for the past month.

Later this year, Maryland officials will start taking applications for social-justice cannabis company licenses. The Social Equity Verification Portal, which MCA unveiled last week, will start letting potential applicants determine whether they qualify for the new licenses this week. Equity candidates will be the only ones eligible for the initial round of new cannabis grower, processor, and store licenses.

Maryland levies a 9% sales tax on cannabis for adult use; medical sales are excluded. This indicates that the policy change has already resulted in a few million dollars entering the state’s coffers.

A prohibitionist organization, Smart Approaches to Marijuana, has criticized the state’s management of tax collection. The group alleges that the state’s Office of the Comptroller was actively working to defend banks that were breaking the law.

The accusation was made following the publication of remarks made by Rob Scheerer, director of the Revenue Administration Division of the Maryland Office of the Comptroller, during a Maryland Association of Counties conference last month. Scheerer stated that to safeguard banks, the term “cannabis” could not be used on tax returns, instead employing the term “a sale subject to the 9% rate under SB516 of 2023.”

Both the Office of the Comptroller and Wells Fargo, its banking partner, have asserted that they adhere to the law.

The surging sales in Maryland suggest that the companies operating within that market could see the kind of success that enterprises such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) have enjoyed in the markets in which they operate.

Curaleaf Holdings Inc. (CURLF), closed Thursday's trading session at $5.39, up 10.3378%, on 694,085 volume. The average volume for the last 3 months is 905,904 and the stock's 52-week low/high is $2.19/$7.90.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, TradersPro, StockEarnings, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A new study published in the “ACS Pharmacology & Translational Science journal has revealed that psychedelics such as psilocybin may combat stress by triggering a temporary increase in stress hormones. The research provides more insight into the potential underlying mechanisms that may allow psychedelics to deliver various mental health benefits.

Psilocybin is a psychedelic compound that occurs naturally in certain mushroom species. It is converted into the active form psilocin when ingested and mainly interacts with serotonin receptors in the brain. The traditional “psychedelic experience’” occurs when psilocin interacts with the serotonin 2A receptor subtype and induces feelings of altered mood, consciousness and perception.

A recent surge in psychedelic-related research found that various psychedelics have the potential to offer long-term relief against several mental-health disorders at low doses and with minimal adverse side effects. Researchers have spent the past few years researching the potential benefits of using psychedelics as alternative treatments for hard-to-treat mental disorders, including post-traumatic stress disorder (PTSD), major depressive disorder and eating disorders.

There has also been a concerted effort to understand how psychedelics interact with the brain to figure out how to develop effective psychedelic-based therapies. These research efforts culminated in a type of therapy called “psychedelic-assisted therapy,” which involves dosing patients with psychedelics and then guiding them through psychedelic experiences before helping them integrate the insights they made during the experience into their lives.

As clinical studies involving psychedelic-assisted therapy have registered incredibly promising results, this type of therapy has attracted plenty of public attention because of its potential to treat conditions such as PTSD and depression long-term.

Cody J. Wenthur, study author, University of Wisconsin–Madison assistant professor and director of Psychoactive Pharmaceutical Investigation Programs, noted that psychedelics such as psilocybin are attracting considerable scientific attention, especially in clinical trials, as support for nondrug, talk-therapy approaches.

With these psychedelic compounds drawing closer and closer to FDA review, Wenthur said gaining an understanding of how psychedelics function on a biological level will be crucial to designing psychedelic-assisted treatments that minimize patient risk and maximize safety. Wenthur and his team used a mouse model to study psilocybin’s pharmacological and biological aspects. They found that a certain dose of psilocybin produced anti-anxiety effects similar to anxiolytic drugs around four hours after initial dosing.

Additionally, the researchers discovered that psilocybin triggered a rapid increase in corticosterone levels in blood plasma, indicating that the stress hormone played a role in psilocybin’s anti-anxiety effects. However, psilocybin didn’t deliver any significant anti-anxiety effects in mice with consistently high corticosterone plasma levels.

As other enterprises such as Seelos Therapeutics Inc. (NASDAQ: SEEL) dig further into understanding how different psychedelics bring about their therapeutic effects, the world could see an array of hallucinogenic-based formulations approved by regulators such as the FDA for treating a variety of mental health and other ailments.

Seelos Therapeutics Inc. (SEEL), closed Thursday's trading session at $0.938, up 0.947051%, on 589,284 volume. The average volume for the last 3 months is 402,845 and the stock's 52-week low/high is $0.58/$1.66.

Royal Gold Inc. (RGLD)

TopStockAnalysts, Streetwise Reports, StreetAuthority Daily, InvestorPlace, TradingAuthority Daily, QualityStocks, Top Pros' Top Picks, The Street, MarketBeat, Daily Wealth, StreetInsider, Daily Trade Alert, SmarTrend Newsletters, Zacks, TheStockAdvisor, All about trends, Energy and Capital, Money Morning, MarketClub Analysis, The Growth Stock Wire, TheStockAdvisors, Trades Of The Day, Dividend Opportunities, Wyatt Investment Research, Marketbeat.com, Uncommon Wisdom, Barchart, Wealth Daily, Lebed.biz, Investor Update, DividendStocks, Daily Profit, Schaeffer's, Investment U, National Inflation Association, TradingMarkets, Money and Markets, The Online Investor, Traders For Cash Flow, Stockhouse, Forbes, Outsider Club, Kiplinger Today, MiningNewsWire, Weekly Wizards, Greenbackers, Market Intelligence Center Alert, Trade of the Week, Wealth Insider Alert, BestChartNow, ChartAdvisor, AllPennyStocks, Dynamic Wealth Report, Eagle Financial Publications, The Best Newsletters, FNNO Newsletters, Bourbon and Bayonets, Stocks That Move, Penny Stock Chaser, PowerRatings Stocks, Profits Run, Short Term Wealth, Market FN, Hit and Run Candle Sticks, Stansberry Research, GorillaTrades, Investopedia, StocksEarning, Investing Futures, Inside Investing Daily, One Hot Stock, INO.com Market Report and Market Authority reported earlier on Royal Gold Inc. (RGLD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

This year has been a great year for mergers and acquisitions in the global gold industry amid record gold purchases by central banks across the world. The biggest news in the gold sector was Newmont Corp.’s $19.2 billion acquisition of Australia-based Newcrest Mining, undoubtedly one of the largest gold producers on the globe.

With the Colorado-based Newmont Corp. playing an equally large role in global gold production, the acquisition cemented Newmont’s status as the undisputed top gold producer. A recent report from Mining Intelligence ranked Newmont as the largest producer of gold at 2,514 koz of the precious metal produced in the first half of 2023.

Acquiring Newcrest Mining granted Newmont access to one of the highest-grade gold mines in the world, the Brucejack Mines. Newmont’s global gold empire also includes running Nevada Gold Mines, in partnership with Barrick Gold.

Canadian miner Barrick Gold ranked as the second-largest gold producer at 1,196 koz of gold produced in the first half of the year. Barrick Gold formed a joint venture with Newmont in early 2019 that would see both miners combine their mining operations, reserves, talent and assets in Nevada in order to access to up to $5 billion in synergies.

Earlier this year, Barrick Gold CEO Mark Bristow said the Canadian miner would be open to taking over Newmont’s stake in the joint venture as Newmont negotiated its takeover deal with Newcrest.

Agnico Eagle Mines ranked third after Newmont and Barrick Gold, producing 1,767 koz of gold from its mining operations in Mexico, Canada, Finland and Australia. Agnico Eagle closed a $10 billion merger with Kirkland Lake Gold in February 2022 and partnered with Pan American Silver to purchase Canadian miner Yamana Gold in a $4.8 billion cash and shares deal earlier this year. The Toronto-based miner also became the sole owner of Canadian Malartic, the second-largest gold mine in the country, in July and began posting record production numbers.

AngloGold Ashanti from Johannesburg, South Africa, ranked as the fourth-largest gold miner in H1 2023, producing 1,138 koz of gold from mines in the Americas, Australia and Africa. Company shareholders recently approved plans to exit the South African market by switching AngloGold’s primary listing to New York and building its new headquarters in London.

Johannesburg-based Goldfields was the fifth-largest gold producer at 1,080 koz of gold from operations in Peru, Australia and Africa followed by Kinross Gold, which produced 1,021 koz of gold in the first half of 2023. Australian miner Newcrest was the seventh-largest gold producer at 987 koz of gold from mines in Canada, Australia and Papua New Guinea.

Northern Star Resources in Australia, Zijin Mining from China and South Africa’s Harmony Gold ranked as the eighth, ninth and tenth gold miners, producing 791 koz, 747 koz and 741 koz of gold respectively.

While the companied mentioned in these ranking pull some weight in the gold industry, other actors such as Royal Gold Inc. (NASDAQ: RGLD) also make decent contributions to ensure that the seemingly endless demand for the yellow metal is met around the world.

Royal Gold Inc. (RGLD), closed Thursday's trading session at $110.62, up 0.755989%, on 367,208 volume. The average volume for the last 3 months is 8.948M and the stock's 52-week low/high is $84.54/$147.82.

QuantumScape Corp. (QS)

InvestorPlace, Schaeffer's, StockEarnings, StocksEarning, MarketClub Analysis, QualityStocks, The Street, The Online Investor, MarketBeat, GreenCarStocks, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, BUYINS.NET, CNBC Breaking News, Green Energy Stocks, wyatt research newsletter, Atomic Trades, Trades Of The Day, Zacks, TipRanks and INO Market Report reported earlier on QuantumScape Corp. (QS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Automakers from across the world showcased innovative and cutting-edge electric vehicle technologies during the recently concluded IAA Mobility 2023 in Munich. The largest mobility festival in the world, IAA Mobility 2023 ran Sept. 5–10, 2023, and attracted multitudes of carmakers from nations such as Germany and China.

Rather than exhibit their efforts at transforming existing vehicle lines into electric vehicles, carmakers displayed next-generation technologies for EVs of the future. This included extensive display screens, augmented reality, 3D printing capabilities for modern EVs for urban regions and novel types of steering wheels.

Some of the next-gen electric cars showcased at the festival featured innovative interior designs that provided drivers and passengers with a lot more room while maximizing comfort and visual appeal. As the electric vehicle age draws nearer, the basic criteria for vehicles may evolve from simply transmission type, performance and aesthetics to encompass other factors.

High-tech display screens may be one such factor. Although automakers have been equipping vehicles with display screens in recent years, they often have low-quality graphics and can be difficult to use. During the recent mobility festival, however, automakers exhibited EVs that projected driving information in extended displays.

BMW’s Vision Neue Klasse projects entertainment and driving information onto the windshield while the Audi Q6 e-tron uses augmented reality to create a display for the driver on the front windshield. The AR technology hones in on the driver’s eye and projects information along the eye’s focus, creating the illusion of high-quality graphics floating roughly 200 meters ahead of the driver.

Mercedez Benz’s CLA Class concept leverages real-time graphics, augmented reality and high-quality screens to provide drivers with the means to easily access information they need. Other electric cars at the festival also had display features such as door-to-door display screens and showcased a general departure from the manual displays of old.

Artificial intelligence (AI) also made a major appearance at the festival as car brands combined AI and in-house software to create borderline sentient voice assistants. The voice assistants can learn the driver’s routines and behaviors and eventually start carrying out certain actions on behalf of the driver. For example, the assistants can decide the best path to take to get home or remind drivers to carry out actions such as opening windows as soon as they enter their vehicles during hot seasons.

Some carmakers also leveraged 3D printing technology to create lighter EVs with higher structural performance. The CUPRA Dark Rebel was developed using 3D printing, with engineers using the technology to mold metal to the EV’s central cabin spine and cover the roomy seats and headrests with 3D knitting fabric. The EV also featured a next-generation steering wheel with crescent-shaped handles adjacent to a display projecting the CUPRA Dark Rebel’s speed.

Electric cars have been at the forefront of innovation in the automobile industry, and automakers are just getting started. As the industry matures, more of these innovative EV technologies will be available to regular drivers.

While the glitzy in-car technologies such as futuristic display screens may have captured people’s attention at the IAA Mobility 2023 event, it is likely that the decisive impact on EV adoption could come from the work being done by companies such as QuantumScape Corp. (NYSE: QS) to revolutionize battery chemistry to address EV range anxiety once and for all.

QuantumScape Corp. (QS), closed Thursday's trading session at $7.14, up 2.2923%, on 4,330,480 volume. The average volume for the last 3 months is 126,401 and the stock's 52-week low/high is $5.11/$13.86.

The QualityStocks Company Corner

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron management will present at the 25th Annual H.C. Wainwright Global Investment Conference scheduled for September 11-13, 2023, in New York

Wa'el Hashad, the company's CEO, will discuss Longeveron's cellular therapy programs in a pre-recorded presentation. Both he and Lisa Locklear, EVP & Chief Financial Officer, will be at the conference to discuss the company's investment strategies and clinical trial progress

The company aims to create awareness among scientists and investors of its clinical trial progress, positive clinical results, and cellular therapy programs

Longeveron is evaluating its lead investigational product candidate, a cellular product named Lomecel-B(TM), in ongoing clinical trials

The product candidate is being advanced as a potential treatment for hypoplastic left heart syndrome ("HLHS"), Aging-related Frailty, and Alzheimer's disease

Longeveron (NASDAQ: LGVN), a clinical-stage company, is focused on developing cellular therapy primarily for conditions with a clear unmet medical need. The company is guided by the mission to advance cell-based product candidates into pivotal Phase 3 trials, with the goal of attaining regulatory approvals and subsequently commercializing the product.

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Thursday's trading session at $2.33, up 0.431034%, on 33,254 volume. The average volume for the last 3 months is 5.74M and the stock's 52-week low/high is $2.2302/$4.935.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave (NYSE: QBTS), a leader in quantum computing systems, software and services and the world's first commercial supplier of quantum computers, has announced notable progress in its development of high coherence qubits. D-Wave has designed, manufactured and operated fluxonium qubits that have demonstrated quantum properties that are comparable to the best seen to date in scientific literature, and the results are expected to have a significant impact on its future quantum technologies.

To view the full press release, visit http://ibn.fm/zqjDq

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Thursday's trading session at $1.07, up 0.943396%, on 2,271,985 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.935/$.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, is announcing new stops on its 2023 Strikingly Different EV U.S. tour. This month the EV experience will be in North Carolina as well as Washington, D.C., Philadelphia, New York City and Boston. This year's Strikingly Different tour began in August, with its first stop in Austin, Texas; the innovative in-person tour is slated to go through November 2023 and includes destinations in the South and Midwest as well as on both the East and West Coasts. Announced tour stops in October include Detroit, Denver, Salt Lake City and Sonoma, California. In November, the tour will head to Las Vegas, Phoenix and Los Angeles. Those visiting the tour will have opportunities to test-drive Mullen vehicles, meet members of the Mullen team and check out the latest EV technology, including AI-powered PERSONA, Mullen's proprietary advanced facial recognition technology. Vehicles included on this fall's tour include the Mullen FIVE EV Crossover, the Mullen FIVE RS High Performance Sport EV Crossover, the Mullen GT High Performance Electric Sports Car, the Mullen ONE class 1 Commercial EV Cargo Van, the Mullen THREE class 3 Commercial Low Cab Forward and the Bollinger B2 Electric Pickup. "We're proud to announce additional locations across the U.S. for our Strikingly Different U.S. EV tour," said Mullen Automotive CEO and chair David Michery in the press release. "More locations equal more opportunity for the public to come out and see our EVs and interact with our team."

To view the Strikingly Different tour schedule, visit https://ibn.fm/5NbLB

To view the full press release, visit http://ibn.fm/QB33W

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.57, up 14.9425%, on 130,886,072 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3901/$137.25.

Recent News

Near Intelligence Inc. (NASDAQ: NIR)

The QualityStocks Daily Newsletter would like to spotlight Near Intelligence Inc. (NASDAQ: NIR).

Near Intelligence (NASDAQ: NIR), a data intelligence platform that curates one of the world's largest sources of intelligence on people and places, has appointed current general counsel Jay Angelo as its new chief privacy officer; Angelo will continue to serve as general counsel as well. According to the announcement, the appointment of seasoned professional Angelo indicates Near's commitment to safeguarding user privacy, a core pillar of the company's foundation. The new role will facilitate and support Near's privacy initiatives, ensuring that the company continues to uphold the highest standards of data protection and privacy compliance.

To view the full press release, visit http://ibn.fm/pSGaT

Near Intelligence Inc. (NASDAQ: NIR), a Privacy-Safe Geospatial Intelligence Platform, curates one of the world’s largest sources of intelligence on people and places. Near’s patented technology analyzes data to deliver insights on approximately 1.6 billion unique user IDs across 70 million points of interest in more than 44 countries. With Near’s three-pillared approach – high-quality data, privacy, and AI – operational and marketing leaders are empowered with solutions to successfully engage and grow their businesses at scale. With a presence in Pasadena, San Francisco, Paris, Bangalore, Singapore, Sydney, and Tokyo, Near serves enterprises in diverse industries, including retail, real estate, restaurants, travel/tourism, telecom, media, and more.

Established in 2012, Near employs vast data volumes to comprehend consumer behavior across digital and physical realms, ensuring privacy compliance through anonymization and aggregation. The company analyzes behavior around visited places and connected devices.

Near is headquartered in Pasadena, California.

Platform and Services

The Near platform delivers global, high-quality data in a privacy-safe environment, evaluating consumer activity across physical and digital spaces to provide business leaders with deep insights into the places their customers frequent, along with their brand and competitor preferences.
It is built on three fundamental tenets:

  • Global, High-Quality Data: The Near Platform provides high-quality insights about people and places from diverse industries and applications. Through complex data refinement processes, Near converts raw data into powerful insights that empower decision-makers with actionable information.
  • Privacy and Transparency: Data privacy and transparency are deeply ingrained in Near’s foundation. The platform is built on the principle of privacy by design, ensuring that data privacy considerations are integrated into every aspect of its products, processes, and practices. The Near approach empowers business decision-makers with control over their information and adheres to the most stringent global privacy regulations.
  • Data Science and AI Innovation: The Near Platform employs advanced algorithms and machine learning models to deliver high-quality insights, so users can decipher complex consumer behavior patterns and trends.

In August 2023, Near illustrated the value of its intelligence platform in one such industry – quick-service restaurants (QSRs). Many of the world’s largest QSR brands count Near as a trusted partner for high-quality data insights and restaurant analytics. By harnessing Near’s advanced analytics capabilities, top QSRs with combined annual revenues approaching $90B are able to understand consumer movement and behavior patterns, brand affinities, trade areas, and trends.

The company also collaborates with partners to strengthen their datasets by integrating Near’s physical and digital world understanding. Near’s data is always delivered with a privacy-first, consent-led approach via its SaaS-based geospatial analytics platform.

Market Outlook

An analysis from Fortune Business Insights estimated the global business intelligence market was valued at $27.11 billion in 2022 and is projected to grow from $29.42 billion in 2023 to $54.27 billion by 2030, a CAGR of 9.1% during the forecast period.

According to the report, global market growth can be attributed to the increasing adoption of cloud-based Artificial Intelligence/Machine Learning services and data analytics across organizations. A surge in demand for flexible architectures and adaptable solutions opens up market expansion opportunities.

Management Team

Anil Mathews is the CEO of Near. He is a visionary who has spent the past 22 years as a serial entrepreneur, building successful businesses around engineering, messaging, and social. He is passionate about creating new market companies with a strategic vision and technology capability that can provide substantial growth. He is also an advisor and investor to numerous startups across the globe.

Shobhit Shukla is President of Near. He currently runs the company’s global business and strategic initiatives, where he is responsible for executing Near’s vision to become the most accurate and privacy-safe source of intelligence on people and places. He holds an MBA from the Indian Institute of Management and advises multiple early-stage startups on growth strategy.

Gladys Kong is COO of Near. She was previously CEO of UberMedia, a data intelligence company acquired by Near. She was also CEO of Go Interactive, a fantasy sports company. Before that, she held Engineering and R&D vice president positions at Snap.com and Idea Lab. She has a bachelor’s degree in engineering and applied science from Caltech and a master’s degree in computer science from UCLA.

Rahul Agarwal is the CFO of Near. He began his career at PwC India and later held accounting and finance roles at HT Media and InMobi, where he rose to the position of Head of Finance, North America. He is a graduate of The Institute of Chartered Accountants of India and holds an MBA in finance and strategy from the Indian Institute of Management at Bangalore.

Near Intelligence Inc. (NASDAQ: NIR), closed Thursday's trading session at $0.38, up 3.8251%, on 246,970 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3519/$18.65.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

First Tellurium (CSE: FTEL) (OTC: FSTTF) president and CEO Tyron Docherty was recently featured as a guest on the Bell2Bell podcast, where he talked about the company and its key position in the growing tellurium space. "First Tellurium has a wonderful, high-grade gold and silver property in Canada, but it comes with this unique mineral, tellurium, which is listed by both the United States and Canadian governments as critical," a recent article quotes Docherty as saying. "Tellurium has come into the fore over the last couple of decades because it is used in solar panels by U.S. corporation First Solar, which uses a mixture of cadmium and tellurium, as opposed to different solar panels coming out of China. Tellurium is very important there, and it's a very rare metal." In addition, Docherty noted, the company's polymetallic Deer Horn property looks to contain the "greenest of all minerals" – copper – which the company plans to start exploring soon. "We really are blessed to have a tremendous property and, to top that off, we've also got the highest-grade tellurium property in North America in a property in Colorado that used to be owned by First Solar. So we're going to be looking at that after, so when it comes to solar potential and tellurium potential, we're the only ones in town, so to speak."

To view the full article, visit https://ibn.fm/NYY69

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

 

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Thursday's trading session at $0.079, up 5.3333%, on 15,458 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.071/$0.1765.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Brigham and Women's Hospital scientists have developed a microdevice to help researchers test the effectiveness of glioma treatments. Gliomas are a type of brain tumor that arise from glial cells in the spinal cord and brain before infiltrating surrounding brain cells. Because the proximity of gliomas to healthy brain cells makes them hard to remove via surgery, glioma treatment often involves removing as much of the tumor via surgery before using chemotherapy or radiation therapy to kill off as many of the remaining cancer cells as possible. Furthermore, researchers find it extremely difficult to test the effects of different drug combinations on glioma cells because each patient can take only one treatment approach at a time, making further research into glioma treatments almost impossible. The new microdevice from Brigham and Women's Hospital is the size and shape of a rice grain and has the potential to enable several simultaneous studies on the effectiveness of different drugs against glioma tumors. Researchers designed the device as a standard-of-care surgery tool and published results from the microdevice's pilot clinical trial in the "Science Translational Medicine" journal. With the help of these micro-devices, the future brain cancer drugs made by enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) could become much more effective against malignancies that have previously been hard to treat.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $1.45, off by 3.9735%, on 16,726 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6105/$8.64.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics(NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology ("I&I") biological products primarily for the treatment of autoimmune and infectious diseases, is reporting encouraging results from its preclinical study of Scinai's antiinterleukin 17 (IL17) NanoAbs as a treatment for plaque psoriasis. According to the report, study results suggest that the NanoAbs, or nanosized VHH antibodies, have potential to relieve symptoms of plaque psoriasis. Currently, there is no safe, affordable biological drug available to treat mild psoriasis, which accounts for 50% of plaque psoriatic patients, has no safe and affordable biological drug available. Scinai's NanoAbs are administered locally to the dermis and are designed to prevent systemic side effects. Exclusively licensed to Scinai, the NanoAb was discovered by Professor Dirk Görlich, director at the Max Planck Institute for Multidisciplinary Sciences, and was tested for neutralization at the laboratory of Professor Matthias Dobbelstein at University Medical Center Göttingen. The two men are Scinai's lead collaborators for development of a pipeline of NanoAb-based inflammation and immunology biological therapeutics for the treatment of autoimmune and infectious diseases such as psoriasis, psoriatic arthritis, asthma, wet AMD and COVID-19. "Results of this recent study suggest the potential for a highly efficacious, specific, yet safer and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients," stated the company in the announcement. "Scinai recently started to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for plaque psoriasis to evaluate the effective dose and schedule of treatment, with in-vivo animal studies anticipated in early 2024."

To view the full press release, visit http://ibn.fm/TPTnQ

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Thursday's trading session at $1.16, off by 11.4504%, on 193,237 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.13/$11.80.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope, Inc. [Nasdaq: KSCP] ("Knightscope" or the "Company"), a leading developer of autonomous security robots and blue light emergency communication systems, is leveraging technology to improve public safety across the country using Amazon Web Services (AWS). In Huntington Park, California Knightscope's K5 Autonomous Security Robot ("ASR) helped reduce calls for service by 10% and crime reports by 46% during its first year of deployment. The City Council subsequently voted unanimously to extend their contract and has recently awarded Knightscope a contract for its 5 th year of service . Knightscope leveraged nearly a dozen AWS services to support this project. Amazon Elastic Compute Cloud (Amazon EC2) was used to create a scalable environment that could expand to meet increasing demand. Amazon CloudTrail helped simplify security analysis, resource change tracking, and troubleshooting.

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Thursday's trading session at $0.9216, off by 0.043384%, on 918,430 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.36/$3.65.

Recent News

Lucy Scientific Discovery Inc. (NASDAQ: LSDI)

The QualityStocks Daily Newsletter would like to spotlight Lucy Scientific Discovery Inc. (NASDAQ: LSDI).

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery, and manufacturing of psychotropic products, recently announced the acquisition of BlueSky Wellness Inc., along with its portfolio of brands, which adds psychotropic products to its catalog and expands its footprint into the global wellness market. BlueSky wellness-focused ecommerce brands include Keoni, Keoni Sport, Blush Wellness and AMMA Healing, which, in each of the last two years, have generated over $20 million in revenue. BlueSky is poised with a variety of products that range from full-spectrum oils to edible goods, gummies, topicals and beauty products. The offerings complement the products and platform of High Times, of which its intellectual property and brand assets were also recently acquired by Lucy Scientific Discovery.

To view the full press release, visit http://ibn.fm/VRVR4

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is an early-stage psychotropics manufacturing company focused on becoming the premier contract research, development and manufacturing organization for the emerging psychotropics-based medicines industry.

The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (APIs) used in controlled substances and their raw material precursors. Lucy Scientific Discovery and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada).

The company’s mission is to make its products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs, including various mental health and addiction disorders. LSDI targets customers that include an increasing number of the leading universities, hospitals and other public, private and government institutions throughout the world that have launched research programs aimed at understanding the therapeutic potential of a range of psychedelic substances.

The company is headquartered in Victoria, British Columbia, Canada.

Products

LSDI produces a variety of high-quality natural, synthetic and biosynthetic products to meet the needs of the rapidly growing psychotropics-based medicines market. The company believes the emerging psychotropics industry will pave the way to a brighter future in mental health and overall wellness. LSDI is dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies.

In Canada, the psychedelic compounds that LSDI is approved to produce under its Dealer’s License are regulated under the Controlled Drugs and Substances Act, or CDSA. Those compounds include:

  • Psilocybin
  • Psilocin
  • Lysergic acid diethylamide, or LSD
  • N,N-Dimethyltryptamine, or N,N-DMT
  • 3,4-Methylenedioxymethamphetamine, or MDMA
  • 4-Bromo-2,5-Dimethoxybenzeneethanamine, or 2C-B

The company also sells its consumer psychotropic products directly online and through retailers. Those products, described as microdose mushroom formulations, include a sleep aid, Twilight, and a mindfulness enhancer, Mindful.

Market Opportunity

According to a report from Global Market Insights, the psychotropics drug market had an estimated value of $20.2 billion in 2022 and is projected to reach a value of nearly $37.6 billion by 2032. That represents a CAGR of 6.4% for the forecast period. Factors driving market growth include the increasing prevalence of mental disorders, technological advancements in drug development, a rising geriatric population and increasing healthcare expenditures, the report states.

A growing awareness of mental health issues and an effort to reduce the stigma surrounding psychiatric disorders have encouraged more individuals to seek help, which in turn boosts the market. In addition, advancements in neuroscience, pharmacology and drug development have led to the discovery of new and more effective central nervous system therapeutics.

Innovative treatments offering better outcomes with fewer side effects attract patients and healthcare providers, also driving market growth.

Management Team

LSDI’s executive team brings deep experience in the development and commercialization of products featuring controlled substances, as well as the navigation of regulatory structures applicable to these products.

Richard Nanula is Chairman and CEO of LSDI. He has more than 35 years of leadership experience at several of the largest companies in the world, having been a senior executive at The Walt Disney Company, Amgen, Colony Capital and Starwood Hotels and Resorts. He has also served as a board member for Boeing Corporation and Starwood Capital, where he provided corporate guidance and oversight. He holds an MBA from Harvard Business School.

Assad J. Kazeminy, Ph.D., is Chief Scientific Officer at LSDI. He previously served as CEO of Irvine Pharmaceutical Services Inc. and Avrio Biopharmaceutical LLC, and he has founded several drug development companies. He has over 30 years of research and development experience in the biopharmaceutical industry. He received his Ph.D. in Pharmaceutical Science and Biochemistry from Esfahan University in Iran. He completed a Post Doctorate course of study at the University of Southern California Medical School, Department of Pharmacology.

Brian Zasitko, CPA, CA, is the company’s CFO. He is a Director of Invictus Accounting Group LLP, a professional services firm providing finance, advisory and accounting services. He also serves as CFO of Lobe Sciences Ltd., a company developing psychedelic compounds as therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. He has an undergraduate degree from Simon Fraser University and a CPA (CA) from Certified Professional Accountants, British Columbia.

Lucy Scientific Discovery Inc. (NASDAQ: LSDI), closed Thursday's trading session at $0.64, off by 1.9908%, on 162,506 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.55/$4.00.

Recent News

SOHM Inc. (OTC: SHMN)

The QualityStocks Daily Newsletter would like to spotlight SOHM Inc. (OTC: SHMN).

U.S.-based generic drug developer SOHM recently announced the addition of two leading officers — Dr. David Aguilar (Ph.D) as Chief Operating Officer and Dr. Krishna Bhat (MD, Ph.D, FACC) as Chief Medical Advisor

The new officers are expected to help direct SOHM's global growth strategy as the company continues to develop and diversify its product offerings, which include a variety of mediums for administering antibiotics, analgesics, anti-inflammatory and anti-cold therapies, as well as vitamins

SOHM also recently announced an LOI to acquire a stem cell disruptive technology and related patents, which include the potential for someday treating damaged hearts via gene editing

The company's global operation is primarily focused on emerging markets in Africa, Latin America, and Southeast Asia

Generic drug manufacturing and distributing innovator SOHM (OTC: SHMN) is strengthening its governing team with the addition of two experienced visionaries committed to helping the company's growth in the pharmaceutical, nutraceutical, and cosmeceutical marketplace.

SOHM Inc. (OTC: SHMN) is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” (Global Prosperity). SOHM was founded in 1998 and is headquartered in Chino Hills, California.

The company’s primary goal is to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier quality and keeping prices affordable. SOHM is dedicated to fully complying with all relevant regulatory prerequisites and upholding the most rigorous industry benchmarks, including the guidelines set forth by WHO-CGMP and USFDA.

Achievements and Milestones

SOHM is a recognized generic pharmaceutical manufacturer, with production and marketing of generic drugs covering all major treatment categories. SOHM also markets innovative formulations and packaging for various therapeutic segments, such as cosmeceuticals, nutraceuticals and OTC oral dosage formulations, with operations spanning India, the Philippines, Uganda, the U.S., the UK and the EU.

SOHM successfully launched a unique and innovative Salic-2 face wash, FōHM by SOHM, during the Oscar after party in Hollywood. The innovative Salic-2 offering in translucent gel form is marketed as an acne medication in the U.S. cosmeceutical market.

With proficiency in both manufacturing and marketing, SOHM stands out. The company holds licenses for producing over 300 products and has established distribution partnerships with firms in the United States, the Philippines and Uganda. Additionally, SOHM’s repertoire includes the launch of an innovative protein supplement, I-Prolec, featuring a distinct composition—a first-of-its-kind in India.

In 2012, SOHM gained recognition as “the most emerging company in the recent past” at the National Integrated Medical Association Conference. The company’s growth was underscored by its inclusion in the roster of ‘Fastest Growing Public Companies’ according to the Orange County Business Journal.

SOHM Today

SOHM brings all of its expertise and market knowledge toward a new vision. The company continues to develop, manufacture and market generic pharmaceutical drugs for various treatment categories. It offers its products in various dosage forms, including tablets and capsules, creams and topicals, ointments and liquids. The company also provides anti-arthritic/analgesics, dermatological drugs, gastrointestinal and respiratory drugs, biotechnology products, anesthetics, immunosuppressive agents and other various treatments. In addition, it offers a skincare line that includes dry dermatoses, mixed skin infection, acne vulgaris and seborrheic dermatitis products.

SOHM markets its products directly and through partner alliance agreements to drug wholesalers, mass merchandisers, chain drug stores and mail-order pharmacies primarily in the U.S. and has previously done business in the Far East, Africa and Southeast Asia. The company is working with its alliance partner in the African continent and Latin American countries.

SOHM has developed a comprehensive marketing strategy encompassing a diverse range of tactics to promote all products. SOHM uses the power of digital marketing channels, social media campaigns and targeted advertising to significantly enhance awareness and recognition of product offerings.

All distribution networks are strengthened through valuable partnerships. SOHM has gained access to the extensive U.S. market through a strategic alliance with different wholesalers catering to C-stores and retailers. The company has likewise partnered with a distribution firm that holds a remarkable network of more than 4,500 independent pharmacy accounts.

Additionally, a strong partnership with a prominent distribution network in New Jersey enables SOHM to facilitate nationwide distribution to big distribution houses, hospitals and retail chain stores which include but are not limited to Walmart, Publix, Sam’s and many more retail giants, thus extending the company’s market presence.

SOHM Long-Term

A report by Grand View Research estimated the global nutraceuticals market at $291.33 billion in 2022 and forecasts expansion at a compound annual growth rate (CAGR) of 9.4% from 2023 to 2030. The report states primary factors driving the market growth are preventive health care, increasing instances of lifestyle-related disorders, and rising consumer focus on health-promoting diets. Additionally, increasing consumer spending power in high-growth economies is projected to contribute to the growing demand for nutraceutical products.

Grand View valued the global NSAID market at $19.55 billion in 2021 and forecast it would expand to nearly $30 billion by 2030, marking a CAGR of 5.36% for the period. Projected growth is attributed to factors like the rising prevalence of chronic pain across the world, coupled with a growing global geriatric population. In addition, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs in treating headaches, migraine, toothaches and menstrual pain is expected to boost market growth.

Fortune Business Insights estimated that the global cosmeceuticals market was worth $54.57 billion in 2022 and projects the market will grow to a value of $96.23 billion by 2029, marking a CAGR of 8.4% during the forecast period. The report credits the projected growth to the prevalence of skin disorders around the world and the inclination of dermatologists to prescribe or recommend these products as compared to other treatments.

SOHM envisions a future where it evolves into a prominent global corporation, expanding its reach across international borders while upholding its fundamental core values. The company aspires to extend its export portfolio to encompass 11 countries, showcasing a robust international presence.

Aiming for financial stability, SOHM is committed to maintaining sufficient working capital to support its growth endeavors. The company’s forward trajectory involves strategic collaborations, mergers with diverse brands and a focused approach to business expansion through vertical integration and a balanced mix of organic and inorganic strategies.

In this pursuit, SOHM is dedicated to establishing its proprietary network of partners within the over the counter (OTC) sector. Furthermore, the company seeks heightened recognition within crucial therapeutic domains, including oncology, HIV, cardiovascular health, diabetes care and skincare-dermatology, solidifying its prominent standing in these pivotal segments.

Management Team

Baron Night is CEO, President, and Director at SOHM Inc. He has over 40 years of experience in various industries with extensive contacts in emerging markets. His leadership and track record are great assets to the company as SOHM continues to strengthen its position and develop large-scale distribution of generic drug lines.

David Aguliar, Ph.D., is the COO of SOHM. He has 22 years of experience in the pharmaceutical industry, including multiple research positions and scientific publications. He has an extensive background in pharmaceutical Chemistry Manufacturing and Controls (CMC), as well as quality assurance experience in preclinical and Investigational New Drug (IND) application filings of allogeneic cell-based therapies. He has a deep understanding of regulatory and clinical pathways, coupled with an extensive scientific and technical background in the fields of pharmaceuticals, biopharmaceuticals and gene editing tools research.

Dr. Krishna Bhat, MD PHD, FACC, has a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which was awarded in recognition of his commitment to excellence in the field of Cardiovascular Care through his leadership as an outstanding physician, researcher, and educator. He is also a recipient of the Miles Canada Fellowship Award and the J. Louis Levesque Fellowship Award from Montreal Heart Institute in Montreal, Canada.

Dewey Rushing is a Senior Compliance Remediation and Quality Professional with over 30 years of experience in Quality Assurance and cGMP Compliance for products regulated by the U.S. Food and Drug Administration (FDA). He served as a trained Consumer Safety Investigator at the FDA and Instructor at the Los Angeles District. He has in-depth knowledge in technology transfer of biologics and pharmaceutical products, as well as validation of manufacturing equipment, facility cleaning and critical utility systems maintenance. He has an extensive background in auditing GMP facilities, implementing quality systems and performing gap assessments of manufacturing processes and facilities. He has also directed remediation projects in response to federal compliance audit observations.

Sowmya Jacob, MBA-PGP, possesses over a decade of accomplished and evolving expertise in human resources management, along with manufacturing and operations management. She earned an MBA, complemented by advanced marketing certifications. Demonstrating a track record of achievement, she excels in cultivating collaborative work environments and orchestrating transformative changes that lead to heightened productivity. With adeptness in business analysis, she has occupied senior managerial roles, showcasing her mastery. An engaged participant in professional circles, she maintains active memberships in SPHR and CHRP.

SOHM Inc. (OTC: SHMN), closed Thursday's trading session at $0.001, off by 9.0909%, on 3,933,616 volume. The average volume for the last 3 months is 9.194M and the stock's 52-week low/high is $0.0005/$0.0018.

Recent News

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF)

The QualityStocks Daily Newsletter would like to spotlight Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF).

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) is a mineral exploration company focused on exploration activities at its newly acquired Cachoeirinha rare earths project (“PCH Project”) in Brazil, as well as delineating high-grade critical rare earth elements (REE) and gallium at its Alces Lake property in Saskatchewan. Other properties in Appia’s portfolio include its Elliot Lake Property in Ontario’s historic mining camp, with a large NI 43-101 uranium and rare earths resource. Fully funded with over $5 million (CDN) in cash, no debt, aggressive exploration currently underway, and experienced management, Appia is progressing rapidly on multiple fronts in highly desired market sectors.

The company is headquartered in Toronto, Canada.

Projects

PCH Project-Brazil

The PCH project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the underlying granite and a carbonatite intrusion to depths greater than 100 meters. Sampling data shows enrichment in rare earth minerals to depths of between eight meters and +30 meters.

In early 2023, Appia announced a definitive agreement to acquire a 70% interest in the PCH Project, which is 17,551 hectares in size and located in the Tocantins Structural Province of the Brasília Fold Belt, Goiás State, Brazil. It is classified as an alkaline intrusive rock occurrence with the potential for highly anomalous REE and Niobium mineralization.

The region around Iporá, a city located roughly 30 km from the PCH Project, has significant mineral exploration and mining activity and well-developed infrastructure.

In July 2023, Appia commenced an aggressive auger and reverse circulation (RC) drill campaign to delineate a potential resource estimate at the PCH project. Initial results at the site revealed significant exploration potential with impressive values that often surpass known ionic clay deposits in Brazil, particularly for the highly valuable heavy rare earths Terbium and Dysprosium.

The auger holes drilled at Target 4 have exhibited a range of total REE grades, ranging from 274 ppm to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE. The valuable rare earths used in magnet applications – praseodymium, neodymium, terbium and dysprosium (Pr, Nd, Tb, and Dy) plus yttrium (Y) accounted for approximately 14% of total rare earths, reaching a maximum of 28.4%. Notably, the deposit also contains anomalous values of niobium and scandium, with average values of 736 ppm for Nb and 62 ppm for scandium in a composite sample from Target 4.

Heavy rare earths (HREEs) show maximum values of 1,624 ppm and average values of 1,291 ppm, primarily as terbium and dysprosium. Light rare earths (LREEs) show maximum values of 14,024 ppm (1.54%) with an average of 1,145 ppm. Neodymium and praseodymium, the main magnetic light rare earths, show respective maximum values of 3,131 ppm (Nd) and 885 ppm (Pr) and average values of 216 ppm (Nd) and 61.7 ppm (Pr). The overall HRRE/LREE ratio has a maximum of 39.5% and an average value of 16.67%.

“Appia is thrilled with the progress made and the promising results thus far,” CEO Tom Drivas stated in a news release. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months.”

Alces Lake Project – Saskatchewan

Appia’s Alces Lake project, located in northern Saskatchewan, encompasses some of the highest-grade total and critical REEs and gallium mineralization in the world, hosted within several surface and near-surface monazite occurrences that remain open at depth and along strike.

Following the company’s acquisition of additional new mineral claims in the area in February 2023, Appia’s Alces Lake claim block now totals 38,522 contiguous hectares (95,191 acres) – 100% owned by the Company.

Appia announced the completion of a NI43-101 technical report on the property in June 2023, providing an update on exploration previously reported in March 2021.The report is available on SEDAR under the company’s profile.

Extensive diamond drilling and geophysics surveys are underway to explore a more than 25-kilometer structural corridor. In July 2023, the company issued an update on its diamond drill program having completed the first phase of drilling at the project’s Magnet Ridge Zone to further test the extent of the mineralization to the south south-east (SSE). President Stephen Burega noted the presence of “continued mineralization at significantly thicker intercepts.”

As part of its 2023 exploration program at Alces Lake, Appia plans to target priority areas that extend SSE from the Wilson, Richard, Charles, Bell, Ivan, Dylan, Dante and AMP zones through the Magnet Ridge Zone and beyond, covering an area extending approximately 20 kilometers in length and 5 to 7 km in width. Appia will also undertake reconnaissance drilling on priority regional geological and geophysical targets in the Western Anomaly area.

Other Projects

  • Appia holds a total of 75,314 hectares (186,106 acres) of land on four uranium claim blocks in the prolific Athabasca Basin (Loranger, North Wollaston, Eastside and Otherside). Exploration plans for these properties are expected to be announced once permits are in hand.
  • Appia also has a 100% interest in 12,545 hectares (31,000 acres), with rare earth element and uranium deposits over five mineralized zones, in the Elliot Lake Camp, Ontario.

Market Opportunity

A report from Mordor Intelligence forecasts the global REE market is expected to grow from 168 million tons in 2023 to 206.25 million tons by 2028, marking a CAGR of 4.19% during the forecast period. The market is gradually improving following the economic and production restrictions of the COVID-19 pandemic.

Factors driving the market’s growth include high demand from emerging economies and the dependency of environmentally friendly technologies on rare earth elements.

According to UxC, one of the nuclear industry’s leading market research and analysis companies, the uranium market is rapidly becoming production-driven, where spot and long-term prices more closely correlate to the marginal cost of uranium production.

Although global reactor requirements are projected to be flat through 2024, UxC forecasts that significant demand growth from 2025 to 2040 will necessitate new production as resources are exhausted at several uranium projects. In addition, a large percentage of production exists in regions of the world with high geopolitical risk, which makes the market vulnerable to future disruptions and price volatility.

Management Team

Tom Drivas is CEO of Appia Rare Earths & Uranium Corp. He is an entrepreneur with over 30 years of experience in various industries, including over 20 years in the mineral resource industry. He is also currently a director of Romios Gold Resources Inc., a publicly traded company he founded in 1995.

Stephen Burega is President of Appia. He brings 16 years of management and operations experience in the mining and natural resources sectors. His extensive emerging markets background, along with a deep understanding of stakeholder management, social development and structured community engagement, position him well to lead Appia’s First Nations community engagements. He is also President and CEO of Romios Gold Resources which is focused on base and precious metal exploration in North America.

Frank van de Water is the company’s CFO. He holds CPA and CA designations and has been involved with international mining, metals and resource companies in North America, Latin America, Europe and Africa for more than 40 years.

Dr. Irvine R. Annesley, Ph.D., is VP Exploration at Appia. He is a licensed geoscientist (P.GEO.) and Professor in Economic (Mining and Mineral Exploration) Geology at École Nationale Supérieure de Géologie in France and an Adjunct Professor in Geology at the University of Saskatchewan. He has over 35 years of global exploration and applied research experience in uranium, gold and base metals exploration, most recently with Athabasca uranium explorer JNR Resources Inc.

Don Hains, P.Geo., is the company’s Consulting Geologist and Qualified Person Consulting Industrial Minerals Expert.

Antonio Vitor is Appia’s Country Manager, Brazil. He has a track record as a portfolio manager and board member. He has held multiple significant positions, including Territory Manager at Shell, as well as Senior Project Planning and Consulting roles at PwC and Petrobras.

Jack Lifton is the company’s Senior Technical Advisor and Consultant. He is an author and lecturer on the market fundamentals of technology metals.

Appia Rare Earths & Uranium Corp. (OTCQX: APAAF), closed Thursday's trading session at $0.1959, up 4.7594%, on 155,271 volume. The average volume for the last 3 months is 132,791 and the stock's 52-week low/high is $0.10/$0.40.

Recent News

Prime Harvest Inc.

The QualityStocks Daily Newsletter would like to spotlight Prime Harvest Inc.

Prime Harvest Inc., based in San Diego, California, is a technology-focused, full-service cannabis company with horizontally diversified operations spanning various segments of the cannabis value chain, from licensing acquisition and compliance management to direct-to-consumer operations. The company is leveraging a long-term strategy of investing in the growth and scale of licensed assets anchored by the power of data-driven technology to expand its footprint throughout California.

Sustainability is key to Prime Harvest’s corporate vision. The company aims to ensure that the communities it serves capture their fair share of the fruits of the industry’s growth, including financial profit, employment opportunities, environmental enrichment and impactful innovation through R&D and education.

The company’s mission is to appeal to the ethos of the cannabis consumer by setting a new operational standard emphasizing accountability, sustainability and community. With this commitment, Prime Harvest continues to work toward positively affecting millions of lives through the creation of a world-class platform that caters to strengthening the commercial cannabis pipeline.

Jaxx Cannabis

Jaxx Cannabis is the flagship brand in Prime Harvest’s portfolio. Through Jaxx Cannabis, the company aims to use technology to facilitate a true customer-centric culture while enhancing the overall craft cannabis experience. Jaxx features an expertly curated selection of premium products from some of the most respected brands in the thriving California market.

Key values serving as the foundation of Jaxx Cannabis include:

  • Creating and nurturing a welcoming culture for all
  • Unlocking the true potential of customer value
  • Being innovative in uncovering new ways to grow both the company and the industry
  • Meeting the wants and needs of consumers to promote profitability
  • Remaining accountable for the results of its operations

It is these values that differentiate Prime Harvest and Jaxx Cannabis in the California cannabis sector.

Brand Partnerships

Prime Harvest works diligently to establish strong alliances with complementary brands that are in alignment with its culture and values. Through a combination of deliberate foresight and strategic action, the company seeks to grow existing cannabis brands and continuously discover new, high-potential performers that are primed for long-term success.

These partnerships enhance Prime Harvest’s efforts to transform the world’s cannabis access and bring its consumers high-quality products that are fair for both people and the planet.

Responsibility

Prime Harvest remains committed to the goal of creating a more sustainable environment, now and in the future. Concern for human beings and the environment can be observed in every facet of its operations, including its ongoing R&D activities dedicated to exploring methods of reducing and repurposing waste into composite materials and exploring the potential of the hemp plant for industrial and wellness contributions.

The company is a proud member of the Community Alliance Program, a foundation that seeks to make a difference in local communities by providing financial assistance for educational programs, housing homeless veterans, creating urban farms, and holding local arts initiatives for children and adults. The program also helps explore the natural healing attributes of medical cannabis through research, development, clinical trials, and advocating for the safe access of cannabis to those in need.

Market Overview

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products.

Legal sales across the U.S. hit a record of $17.5 billion in 2020, marking an increase of 46% over 2019, according to Forbes. This strong growth is expected to continue. According to a Grand View Research report, the global legal marijuana market is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028.

California – Prime Harvest’s home state – has consistently led the pack in terms of U.S. cannabis sales. The Motley Fool pegged cannabis spending in the Golden State at $3.8 billion in 2020, more than doubling the second state on its list.

Leadership Team

The Prime Harvest team is composed of true experts in their respective fields focused on building a world-class organization capable of driving the cannabis industry and movement forward.

E. Duane Alexander is the company’s Founder and CEO. He brings to the team more than 25 years of real-world, hands-on cannabis retail, marketing and commercial operations experience. Mr. Alexander has championed 40+ cannabis license applications throughout the western U.S. to date.

John Wilczak is the COO of Prime Harvest. He has 30+ years of executive management, strategy development & configuration experience with GE, pharmaceutical and agriculture companies. Mr. Wilczak is a Brown & Columbia MBA with vast knowledge of technology driven intellectual properties.

Andrea Jenson is the Chief Financial Officer of Prime Harvest. As CFO, she is responsible for all the company’s financial functions, including accounting, corporate finance and investor relations. Her career spans more than 20 years of varied experience in financial management, business leadership and financial strategy.

John Kazanjian is the VP of Business Development of Prime Harvest. He has worked over 40 years in business operations, brand marketing, sales and investor/lender communications. Mr. Kazanjian earned his B.S. from Rutgers University and his MBA from Harvard University.

Johann Balbuena is the Chief Marketing Officer of Prime Harvest. She has more than six years of experience in California cannabis licensing acquisition and compliance management. Ms. Balbuena has led multimedia production and content marketing efforts for the likes of the Social Club TV app, The Emerald Cup, High Times, Weedmaps and Synergy.


Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.